Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 22 studies | 39% ± 16% | |
astrocyte | 16 studies | 43% ± 20% | |
oligodendrocyte | 12 studies | 50% ± 18% | |
oligodendrocyte precursor cell | 12 studies | 59% ± 22% | |
fibroblast | 12 studies | 37% ± 15% | |
pericyte | 11 studies | 34% ± 15% | |
microglial cell | 11 studies | 41% ± 14% | |
glutamatergic neuron | 10 studies | 56% ± 23% | |
macrophage | 10 studies | 35% ± 14% | |
GABAergic neuron | 9 studies | 55% ± 21% | |
adipocyte | 9 studies | 30% ± 9% | |
smooth muscle cell | 9 studies | 29% ± 9% | |
epithelial cell | 8 studies | 37% ± 17% | |
neuron | 7 studies | 51% ± 24% | |
ciliated cell | 7 studies | 32% ± 16% | |
retinal ganglion cell | 6 studies | 39% ± 23% | |
mast cell | 6 studies | 22% ± 6% | |
endothelial cell of lymphatic vessel | 6 studies | 38% ± 15% | |
interneuron | 5 studies | 70% ± 20% | |
cardiac muscle cell | 5 studies | 28% ± 6% | |
dendritic cell | 5 studies | 19% ± 3% | |
T cell | 5 studies | 24% ± 5% | |
monocyte | 5 studies | 26% ± 5% | |
type I pneumocyte | 5 studies | 33% ± 9% | |
type II pneumocyte | 5 studies | 31% ± 8% | |
granule cell | 4 studies | 49% ± 6% | |
B cell | 4 studies | 26% ± 6% | |
mesothelial cell | 4 studies | 35% ± 10% | |
Mueller cell | 4 studies | 44% ± 20% | |
amacrine cell | 4 studies | 41% ± 13% | |
retina horizontal cell | 4 studies | 47% ± 17% | |
retinal cone cell | 4 studies | 35% ± 14% | |
retinal rod cell | 4 studies | 41% ± 9% | |
club cell | 4 studies | 35% ± 10% | |
basal cell | 4 studies | 39% ± 25% | |
differentiation-committed oligodendrocyte precursor | 3 studies | 57% ± 8% | |
glial cell | 3 studies | 35% ± 10% | |
progenitor cell | 3 studies | 41% ± 6% | |
plasma cell | 3 studies | 26% ± 6% | |
CD4-positive, alpha-beta T cell | 3 studies | 22% ± 1% | |
vein endothelial cell | 3 studies | 36% ± 22% | |
GABAergic amacrine cell | 3 studies | 49% ± 12% | |
ON-bipolar cell | 3 studies | 35% ± 14% | |
glycinergic amacrine cell | 3 studies | 41% ± 10% | |
myeloid cell | 3 studies | 25% ± 3% | |
endothelial cell of vascular tree | 3 studies | 36% ± 21% | |
hepatocyte | 3 studies | 59% ± 17% | |
retinal pigment epithelial cell | 3 studies | 40% ± 29% | |
abnormal cell | 3 studies | 35% ± 24% | |
connective tissue cell | 3 studies | 29% ± 10% | |
alveolar macrophage | 3 studies | 32% ± 7% | |
capillary endothelial cell | 3 studies | 27% ± 3% | |
natural killer cell | 3 studies | 26% ± 2% | |
respiratory goblet cell | 3 studies | 38% ± 14% | |
lymphocyte | 3 studies | 37% ± 17% | |
muscle cell | 3 studies | 36% ± 27% | |
goblet cell | 3 studies | 40% ± 30% | |
transit amplifying cell | 3 studies | 42% ± 33% | |
mucus secreting cell | 3 studies | 31% ± 8% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 100% | 4879.56 | 2642 / 2642 | 100% | 32.32 | 705 / 705 |
esophagus | 100% | 2814.52 | 1445 / 1445 | 100% | 16.49 | 183 / 183 |
thymus | 100% | 3648.22 | 653 / 653 | 99% | 15.72 | 599 / 605 |
skin | 100% | 4221.39 | 1809 / 1809 | 99% | 19.74 | 466 / 472 |
breast | 100% | 3390.15 | 459 / 459 | 99% | 15.77 | 1103 / 1118 |
lung | 100% | 2987.92 | 577 / 578 | 99% | 10.92 | 1139 / 1155 |
prostate | 100% | 3274.40 | 245 / 245 | 98% | 11.43 | 491 / 502 |
stomach | 100% | 2339.08 | 359 / 359 | 98% | 12.69 | 279 / 286 |
kidney | 100% | 2027.02 | 89 / 89 | 97% | 11.87 | 874 / 901 |
intestine | 100% | 3286.15 | 966 / 966 | 97% | 10.09 | 511 / 527 |
adrenal gland | 100% | 2932.26 | 258 / 258 | 97% | 14.97 | 223 / 230 |
pancreas | 99% | 1898.48 | 325 / 328 | 98% | 10.27 | 174 / 178 |
ovary | 100% | 4627.53 | 180 / 180 | 97% | 10.07 | 415 / 430 |
uterus | 100% | 4275.05 | 170 / 170 | 96% | 10.91 | 440 / 459 |
bladder | 100% | 3543.62 | 21 / 21 | 95% | 9.13 | 480 / 504 |
liver | 100% | 1721.19 | 226 / 226 | 68% | 4.70 | 277 / 406 |
adipose | 100% | 3057.24 | 1204 / 1204 | 0% | 0 | 0 / 0 |
muscle | 100% | 4586.21 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 2750.08 | 241 / 241 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 3285.44 | 1334 / 1335 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 98% | 12.78 | 44 / 45 |
heart | 96% | 2053.28 | 830 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 96% | 12.93 | 77 / 80 |
lymph node | 0% | 0 | 0 / 0 | 90% | 7.53 | 26 / 29 |
peripheral blood | 73% | 1471.03 | 678 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0018105 | Biological process | peptidyl-serine phosphorylation |
GO_1904355 | Biological process | positive regulation of telomere capping |
GO_0000209 | Biological process | protein polyubiquitination |
GO_0051028 | Biological process | mRNA transport |
GO_0090263 | Biological process | positive regulation of canonical Wnt signaling pathway |
GO_1904908 | Biological process | negative regulation of maintenance of mitotic sister chromatid cohesion, telomeric |
GO_0007052 | Biological process | mitotic spindle organization |
GO_0018107 | Biological process | peptidyl-threonine phosphorylation |
GO_0051301 | Biological process | cell division |
GO_1904357 | Biological process | negative regulation of telomere maintenance via telomere lengthening |
GO_0032210 | Biological process | regulation of telomere maintenance via telomerase |
GO_0070198 | Biological process | protein localization to chromosome, telomeric region |
GO_0070212 | Biological process | protein poly-ADP-ribosylation |
GO_0051225 | Biological process | spindle assembly |
GO_0051973 | Biological process | positive regulation of telomerase activity |
GO_1904743 | Biological process | negative regulation of telomeric DNA binding |
GO_0015031 | Biological process | protein transport |
GO_0016055 | Biological process | Wnt signaling pathway |
GO_0070213 | Biological process | protein auto-ADP-ribosylation |
GO_0032212 | Biological process | positive regulation of telomere maintenance via telomerase |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0097431 | Cellular component | mitotic spindle pole |
GO_0005643 | Cellular component | nuclear pore |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005794 | Cellular component | Golgi apparatus |
GO_0000139 | Cellular component | Golgi membrane |
GO_0016604 | Cellular component | nuclear body |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0000242 | Cellular component | pericentriolar material |
GO_0000781 | Cellular component | chromosome, telomeric region |
GO_0031965 | Cellular component | nuclear membrane |
GO_0005634 | Cellular component | nucleus |
GO_0016779 | Molecular function | nucleotidyltransferase activity |
GO_0003950 | Molecular function | NAD+ ADP-ribosyltransferase activity |
GO_0042393 | Molecular function | histone binding |
GO_0008270 | Molecular function | zinc ion binding |
GO_1990404 | Molecular function | NAD+-protein ADP-ribosyltransferase activity |
GO_0005515 | Molecular function | protein binding |
Gene name | TNKS |
Protein name | Tankyrase Poly [ADP-ribose] polymerase tankyrase-1 (EC 2.4.2.30) (ADP-ribosyltransferase diphtheria toxin-like 5) (ARTD5) (Poly [ADP-ribose] polymerase 5A) (Protein poly-ADP-ribosyltransferase tankyrase-1) (EC 2.4.2.-) (TNKS-1) (TRF1-interacting ankyrin-related ADP-ribose polymerase) (Tankyrase I) (Tankyrase-1) (TANK1) Poly [ADP-ribose] polymerase (PARP) (EC 2.4.2.-) |
Synonyms | TINF1 PARPL PARP5A TNKS1 TIN1 |
Description | FUNCTION: Poly-ADP-ribosyltransferase involved in various processes such as Wnt signaling pathway, telomere length and vesicle trafficking . Acts as an activator of the Wnt signaling pathway by mediating poly-ADP-ribosylation (PARsylation) of AXIN1 and AXIN2, 2 key components of the beta-catenin destruction complex: poly-ADP-ribosylated target proteins are recognized by RNF146, which mediates their ubiquitination and subsequent degradation . Also mediates PARsylation of BLZF1 and CASC3, followed by recruitment of RNF146 and subsequent ubiquitination . Mediates PARsylation of TERF1, thereby contributing to the regulation of telomere length . Involved in centrosome maturation during prometaphase by mediating PARsylation of HEPACAM2/MIKI . May also regulate vesicle trafficking and modulate the subcellular distribution of SLC2A4/GLUT4-vesicles . May be involved in spindle pole assembly through PARsylation of NUMA1 . Stimulates 26S proteasome activity . . |
Accessions | ENST00000646522.2 [O95271-1] ENST00000518635.2 ENST00000517770.2 A0AA34QVM1 O95271 ENST00000520408.5 E7EWY6 E7EQ52 ENST00000310430.11 [O95271-1] ENST00000519930.2 A0A0C4DGE3 ENST00000518281.5 E5RHD2 H0YAW5 ENST00000522110.1 |